145 related articles for article (PubMed ID: 37380046)
1. A specific RAGE-binding peptide inhibits triple negative breast cancer growth through blocking of Erk1/2/NF-κB pathway.
Dai X; Hou Y; Deng T; Lin G; Cao Y; Yu G; Wei W; Zheng Q; Huang L; Ma S
Eur J Pharmacol; 2023 Sep; 954():175861. PubMed ID: 37380046
[TBL] [Abstract][Full Text] [Related]
2. Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.
Arora R; Yates C; Gary BD; McClellan S; Tan M; Xi Y; Reed E; Piazza GA; Owen LB; Dean-Colomb W
PLoS One; 2014; 9(6):e98370. PubMed ID: 24896091
[TBL] [Abstract][Full Text] [Related]
3. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
[TBL] [Abstract][Full Text] [Related]
4. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway.
Wang L; Kang FB; Wang J; Yang C; He DW
Anticancer Drugs; 2019 Mar; 30(3):225-232. PubMed ID: 30334817
[TBL] [Abstract][Full Text] [Related]
6. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.
Ananthula S; Sinha A; El Gassim M; Batth S; Marshall GD; Gardner LH; Shimizu Y; ElShamy WM
Oncotarget; 2016 Apr; 7(15):20869-89. PubMed ID: 26989079
[TBL] [Abstract][Full Text] [Related]
7. GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-κB Signaling Pathway.
Li C; Geng C
Biol Pharm Bull; 2023; 46(2):209-218. PubMed ID: 36724950
[TBL] [Abstract][Full Text] [Related]
8. Inhibited Expression of NLRP12 Promotes the Development of Triple-Negative Breast Cancer by Activating the NF-κB Pathway.
Kuang W; Gu Q; Zhou Y; Xiao X; He D; Deng Q
Cell Biochem Biophys; 2023 Dec; 81(4):727-735. PubMed ID: 37658975
[TBL] [Abstract][Full Text] [Related]
9. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
10. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
11. Sanguinarine Inhibition of TNF-α-Induced CCL2, IKBKE/NF-κB/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells.
Messeha SS; Zarmouh NO; Antonie L; Soliman KFA
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955463
[TBL] [Abstract][Full Text] [Related]
12. Hydroxypropyl-β-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity.
Zhu M; Zhao Q; Zhang W; Xu H; Zhang B; Zhang S; Duan Y; Liao C; Yang X; Chen Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111168. PubMed ID: 37939513
[TBL] [Abstract][Full Text] [Related]
13. RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer.
Pujals M; Mayans C; Bellio C; Méndez O; Greco E; Fasani R; Alemany-Chavarria M; Zamora E; Padilla L; Mitjans F; Nuciforo P; Canals F; Nonell L; Abad M; Saura C; Tabernero J; Villanueva J
Oncogene; 2023 Aug; 42(35):2610-2628. PubMed ID: 37468678
[TBL] [Abstract][Full Text] [Related]
14. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
16. ROR activation by Nobiletin enhances antitumor efficacy via suppression of IκB/NF-κB signaling in triple-negative breast cancer.
Kim E; Kim YJ; Ji Z; Kang JM; Wirianto M; Paudel KR; Smith JA; Ono K; Kim JA; Eckel-Mahan K; Zhou X; Lee HK; Yoo JY; Yoo SH; Chen Z
Cell Death Dis; 2022 Apr; 13(4):374. PubMed ID: 35440077
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway.
Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W
Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485
[TBL] [Abstract][Full Text] [Related]
18. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
19. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition.
Yin C; Li H; Zhang B; Liu Y; Lu G; Lu S; Sun L; Qi Y; Li X; Chen W
Breast Cancer Res Treat; 2013 Nov; 142(2):297-309. PubMed ID: 24177755
[TBL] [Abstract][Full Text] [Related]
20. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
Lou L; Yu Z; Wang Y; Wang S; Zhao Y
Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
